ReviewExtracorporeal photopheresis: Past, present, and future
Section snippets
The development of ECP in CTCL
CTCL describes a heterogeneous group of rare lymphoproliferative disorders that are characterized by the accumulation of malignant T-cell clones that home to the skin. The most common form of the disease is mycosis fungoides (MF), which accounts for approximately 60% of new cases. Treatment in the early stages usually involves skin-directed therapies, systemic therapies being used if the disease progresses or for those who present with more advanced-stage MF.1 In the rarer manifestation of
A recommended therapy in CTCL
ECP is now a well-established therapy for CTCL. The original study of ECP in patients with treatment-resistant CTCL reported a response in 27 of 37 patients, showing an average of 64% reduction in cutaneous involvement.3 Since then, numerous studies have been conducted (see review by Knobler and Jantschitsch5). A meta-analysis of 19 studies in patients at all stages of CTCL reported a combined overall response rate of 55.5% with ECP used as monotherapy and 55.7% when used in combination with
ECP may improve skin involvement in systemic sclerosis
Systemic sclerosis is an autoimmune disorder characterized by abnormal deposition of collagen and obliterative vasculopathy in the skin and visceral organs, such as the kidneys, heart, lungs, and gastrointestinal tract. In its severe, progressive form, systemic sclerosis is associated with a pronounced increase in mortality and, as it is an uncommon and heterogeneous condition, few treatments have been tested systematically.
Small pilot studies indicated that ECP had beneficial clinical effects
ECP in the treatment of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis
Nephrogenic fibrosing dermopathy, a recently described entity that is also called nephrogenic systemic fibrosis, occurs in patients with renal insufficiency. It is associated with fibrosis of the skin and internal organs, and has some characteristics reminiscent of systemic sclerosis, scleromyxedema, and eosinophilic fasciitis.26, 27 Exposure to gadolinium, a contrast agent used in imaging, seems to be closely associated with triggering the disease.28 Effective treatment remains a challenge,
ECP is highly effective in GVHD
GVHD is a serious and frequent complication of allogeneic hematopoietic stem cell transplantation, and contributes substantially to posttransplantation morbidity and mortality. Established first-line therapy consists of corticosteroids, and nonresponding patients require additional immunosuppressive therapies that may impair immune function, leading to life-threatening opportunistic infections and other therapy-related complications.
Early studies with ECP indicated that this therapy may be
Promising results with ECP in solid organ transplant rejection
Because graft rejection after organ transplantation is another T cell–mediated disease, ECP has been investigated in this indication. Early studies in small numbers of patients undergoing cardiac transplantation indicated that ECP plus conventional immunosuppressant treatment could reduce the incidence of rejection episodes among those at high risk of rejection, and reduce or reverse rejection in patients who have developed severe, recurrent, or refractory rejection.49, 50, 51, 52, 53 In
Promising pilot studies on ECP in CD
CD is a relapsing, progressive, T cell–mediated inflammatory disorder.65 Standard treatment consists of systemic steroids and salicylate for mild disease and systemic steroids, immunomodulators, and/or anti-tumor necrosis factor (TNF)-α inhibitors for moderate to severe disease. However, a large proportion of patients develop either steroid dependency or resistance, resulting in long-term use of high doses of these drugs and high risk of treatment-related complications. In a small preliminary
ECP in other diseases
A series of small open studies in patients with severe, treatment-resistant atopic dermatitis has indicated that ECP is effective in selected patients with this condition. Patients who failed to respond to standard first- and/or second-line therapies showed substantial skin responses to ECP treatment within 6 to 10 cycles.69, 70, 71 In the largest study to date, 35 patients with severe, therapy-resistant atopic dermatitis showed a significant overall reduction in Scoring of Atopic Dermatitis
Mechanism of action of ECP
While studies continue to accumulate showing the promising efficacy of ECP in many disease areas, progress is also being made in the search for understanding of the mechanisms of action, which will ultimately facilitate improvements in the use of this therapy.
Extracorporeally administered 8-MOP in the presence of UVA radiation forms covalent bonds with pyrimidine bases of nucleic acids, and DNA strand breaks are produced adjacent to these covalent bonds, along with cross-linking of DNA strands.
Safety and tolerability of ECP
ECP is a well-tolerated therapy. No significant side effects of this therapy have been reported in any of the conditions reviewed here, except for the short-term effects of oral 8-MOP when this was used in early studies. A reduction in red blood cell count and platelet count has been observed in some patients with acute GVHD. In addition, there is a risk of catheter-related infections if central venous lines are used, and rare cases of hypotension have been reported.33, 37, 47 Unlike other
Conclusions
ECP is an established first-line therapy for CTCL. This treatment has also now shown good efficacy in a number of other severe and difficult-to-treat conditions, such as systemic sclerosis, acute and chronic GVHD, and allograft rejection. Moreover, in a number of conditions, the use of ECP may allow many patients to reduce their use of systemic steroids and other immunosuppressants, thus reducing their long-term morbidity and mortality. The data accumulated during more than 20 years of use
References (94)
- et al.
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
Eur J Cancer
(2006) - et al.
Parenteral administration of 8-methoxypsoralen in photopheresis
J Am Acad Dermatol
(1993) - et al.
Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma
Transfus Apher Sci
(2003) - et al.
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution
J Am Acad Dermatol
(1996) - et al.
Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma
Lancet
(1997) - et al.
Optimizing bexarotene therapy for cutaneous T-cell lymphoma
J Am Acad Dermatol
(2002) - et al.
Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome
Mayo Clin Proc
(2002) - et al.
High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome
Clin Lymphoma Myeloma
(2006) - et al.
Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)
J Am Acad Dermatol
(1999) - et al.
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis
J Am Acad Dermatol
(2006)
Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy
Am J Kidney Dis
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease
J Am Acad Dermatol
Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
Blood
Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study
Blood
Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs-host disease
Biol Blood Marrow Transplant
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
Blood
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
Blood
Successful reversal of severe refractory cardiac allograft rejection by photopheresis
J Heart Lung Transplant
Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis
J Heart Lung Transplant
Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation
Chest
Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis
J Thorac Cardiovasc Surg
Successful reversal of recalcitrant hepatic allograft rejection by photopheresis
Liver Transpl
The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients
Transplant Proc
Refractory acute renal allograft rejection successfully treated with photopheresis
Transplant Proc
Successful monotherapy of severe and intractable atopic dermatitis by photopheresis
J Am Acad Dermatol
Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis
J Am Acad Dermatol
Extracorporeal photochemotherapy for chronic erosive lichen planus
Lancet
Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis
J Am Acad Dermatol
Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis
J Invest Dermatol
Extracorporeal photochemotherapy: a historical perspective
Transfus Apher Sci
Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens
J Am Acad Dermatol
Photopheresis: clinical applications and mechanism of action
J Investig Dermatol Symp Proc
Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease
Blood
Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease
Blood
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells
Blood
Staging and management of cutaneous T-cell lymphoma
Clin Exp Dermatol
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results
N Engl J Med
The treatment of cutaneous T-cell lymphoma with photopheresis
Dermatol Ther
Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy: clinical, molecular, and immunologic observations
Arch Dermatol
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome
Arch Dermatol
Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution
Arch Dermatol
Treatment of autoimmune disease with extracorporeal photochemotherapy: progressive systemic sclerosis
Yale J Biol Med
Three cases of progressive systemic sclerosis treated with extracorporeal photochemotherapy
Arch Dermatol Res
The effect of extracorporeal photochemotherapy on alpha1(I) and alpha1(III) procollagen mRNA expression in systemic sclerosis skin tissue
Arch Dermatol Res
Quantitative echographic analysis of photochemotherapy on systemic sclerosis skin
Arch Dermatol Res
Management of severe scleroderma with long-term extracorporeal photopheresis
Dermatology
Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis: an Austrian single-center study
Photodermatol Photoimmunol Photomed
Cited by (0)
Supported by an unrestricted educational grant from Therakos.
Disclosure: Dr Knobler is a consultant, investigator, and speaker for Therakos. Dr Couriel is on the Advisory Board for Genzyme; is an investigator for Genzyme, Cephalon, and Astellas; and a speaker for Therakos, Schering Plough, Pfizer, Genzyme, Astellas, and Kirin. Dr Ferrara is a consultant for Therakos. Dr Jaksch is a speaker for Therakos. Dr Reinisch is a consultant, investigator, and speaker for Therakos. Dr Rook is a consultant for Merck and Graceway, and a speaker for Therakos and Eisai. Dr Schwarz is on the Advisory Board for Therakos, Novartis, Agiderm, Abbott, Intendis, Allmiral, and Genmab and a stockholder of Agiderm. Dr Greinix is on the Advisory Board and an investigator and speaker for Therakos. Drs Barr and French have no conflicts of interest to declare.
This article was prepared by Ann McIlhinney, DPhil, of Anagram Communications Ltd, funded by Therakos, on behalf of the authors and is based on the presentations at a symposium held in the Vienna General Hospital of the Medical University of Vienna in 2007.